Shielding of magnetic field as a medical therapy
AssigneeMicromed Scientia, Inc.
InventorJiu Xiang NI
Life of this patent
Estimating the term…
Abstract
Provided are methods for disrupting dipolar interactions in vivo and in vitro, as wells as treating conditions associated with abnormal cell growth, by subjecting to an artificial, stable magnetic field. Also provided are assays involving an artificial, stable magnetic field. Additionally, the exposure of an artificial, stable magnetic field may be combined with other non-magnetic therapy in treatment or assays.
Claims21
A method for disrupting dipolar molecular interactions in a cell comprising subjecting the cell to an artificial, stable magnetic field for a period of time sufficient to result in altered dipolar interactions between molecules in said cell so as to alter the cellular physiology.
A method for reducing undesired cell proliferation in a mammal which method comprises placing said mammal in an artificial, stable magnetic field which alters the physiology of proliferative cells thereby reducing their rate of proliferation.
A method for inhibiting tumor metastasis in a mammal which method comprises placing said mammal in an artificial, stable magnetic field for a period of time sufficient to alter the physiology of cells undergoing undesired proliferation at a secondary site that is different from the primary site of said mammal thereby reducing the rate of undesired cell proliferation at the secondary site.
A device for mammalian therapy comprising an artificial, stabilized magnetic field, wherein said device permits said mammal to experience the artificial stabilized magnetic field for a therapeutically effective time.
An assay for ascertaining the optimal condition of an artificial magnetic field therapy to maximize the therapeutic results for pathological cell growth, wherein said assay comprising:
- (a) isolating pathological cells from a mammal for in vitro culturing;
- (b) subjecting cell culture(s) of step (a) to a plurality of artificial magnetic fields wherein each of said artificial magnetic fields is maintained under different conditions from said other artificial magnetic fields;
- (c) comparing the growth of cell cultures in each of said artificial magnetic fields;
- (d) optionally repeating steps (a) through (c);
- and
- (e) determining the optimal condition of said artificial magnetic field based on the results of steps (a) through (d).
A method for developing an in vivo personalized treatment comprising:
- (a) conducting an in vitro assay for ascertaining the optimal condition of an artificial magnetic field therapy to maximize the therapeutic results for pathological cell growth, wherein the assay comprises:
- (i) isolating pathological cells from a mammal for in vitro culturing;
- (ii) subjecting cell culture(s) of step (i) to a plurality of artificial magnetic fields wherein each of said artificial magnetic fields is maintained under different conditions from said other artificial magnetic fields;
- (iii) comparing the growth of cell cultures in each of said artificial magnetic fields;
- (iv) optionally repeating steps (i) through (iii);
- and
- (v) determining the optimal condition of said artificial magnetic field based on the results of steps (i) through (iv);
- (b) correlating the optimal condition based on the in vitro assay and the condition of the in vivo treatment.
A method for evaluating the therapeutic effect of a non-magnetic treatment for reducing undesired cell proliferation in a mammal which method comprises:
- (a) administering said non-magnetic treatment to said mammal;
- (b) placing said mammal in an artificial, stable magnetic field which alters the physiology of proliferative cells before, during, or after administration of said non-magnetic treatment;
- (c) comparing the growth of undesired cells before step (a) with the growth of undesired cells after step (b) to select the non-magnetic treatment that results in reduced growth of undesired cells after step (b).
An in vitro assay for an anti-tumor agent comprising:
- (a) isolating pathological cells from a mammal for in vitro culturing;
- (b) culturing cell culture(s) of step (a) in the presence of said anti-tumor agent under the condition of being subjected to an artificial, stable magnetic field and under the condition of being free of said magnetic field;
- (c) comparing the growth of cell cultures under each condition;
- (d) selecting the anti-tumor agent which causes more cell death under the condition of being subjected to said magnetic field than under the condition of being free of said magnetic field.
A method for determining a reduced effective dose of an anti-tumor agent comprising:
- (a) isolating pathological cells from a mammal for in vitro culturing;
- (b) culturing cell culture(s) of step (a) in the presence of said anti-tumor agent at various doses under the condition of being subjected to an artificial, stable magnetic field and under the condition of being free of said magnetic field;
- (c) comparing the growth of cell cultures treated with various doses of said anti-tumor agent under each condition;
- (d) determining a dose of said anti-tumor agent under the condition of being subjected to an artificial, stable magnetic field, which dose achieves the same reduction in cell growth but is lower than the dose under the condition of being free of said magnetic field.
Dependencies are inferred from the claim text.